Ligand Pharmaceuticals (LGND) Debt Ratio (2011 - 2026)

Ligand Pharmaceuticals (LGND) reported Debt Ratio of 0.29 for Q1 2026, up 2.02% sequentially from 0.29 in Q4 2025.

Ligand Pharmaceuticals (LGND) Debt Ratio (2011 - 2026) Analysis & Trends

Ligand Pharmaceuticals (LGND) has 13 years of Debt Ratio data on file, last reported at 0.29 in Q1 2026.

For the quarter ending Q1 2026, Debt Ratio changed N/A year-over-year to 0.29; the trailing twelve-month figure through Mar 2026 stood at 0.29 (changed N/A YoY), and the FY2025 full-year result was 0.29, changed N/A from the prior year.
Debt Ratio improved to 0.29 in Q1 2026, from 0.29 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.3 in Q3 2025 to a low of 0.07 in Q3 2022.
A 4-year average of 0.18 and a median of 0.11 in 2022 frame the typical range for Debt Ratio.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	1.41
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.11
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.05
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Ligand Pharmaceuticals	6.05 Bn	5.27 Bn	48.45 Mn	0.29

Download Data